Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Essex Bio-TechnologyHKSE:01061 +0.88%86 Interest Coverage is 28.89 as of Jun. 2026, which is 28% below its 10-year median of 39.95. GuruFocus rates HKSE:01061 with a GF Score™ of 86/100 and a GF Value™ of HK$3.13 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 685 Drug Manufacturers companies, Essex Bio-Technology ranks better than 66.28% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Essex Bio-Technology's
Operating Income
for the
six
months ended in Jun. 2026 was HK$134 Mil. Essex Bio-Technology's Interest Expense for the
six
months ended in Jun. 2026 was HK$-5 Mil.
Essex Bio-Technology's interest coverage for the quarter that ended in Jun. 2026 was 28.89.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Essex Bio-Technology's Interest Coverage or its related term are showing as below:
HKSE:01061'
s Interest Coverage Range Over the Past 10 Years
Min: 17.08 Med: 39.95 Max: 154.93
Current: 35.09
HKSE:01061's Interest Coverage is ranked better than 66.28% of 685
companies
in the Drug Manufacturers industry
Industry Median: 13.55
vs HKSE:01061: 35.09
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Essex Bio-Technology Interest Coverage Related Terms
Essex Bio-Technology Interest Coverage Historical Data
* Premium members only.
The historical data trend for Essex Bio-Technology's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Essex Bio-Technology's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Essex Bio-Technology Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Essex Bio-Technology's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Essex Bio-Technology's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Essex Bio-Technology (HKSE:01061) has a Interest Coverage of 28.89 as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Essex Bio-Technology and its competitors. This is 28% below median its historical median of 39.95. Over the past decade, Essex Bio-Technology's Interest Coverage has ranged from 17.08 to 154.93. According to the industry distribution chart, Essex Bio-Technology ranks #231 out of 685 companies in the Drug Manufacturers industry, placing it in the top 33.7%.
Is Essex Bio-Technology's Interest Coverage too high?
Essex Bio-Technology's current Interest Coverage of 28.89 is 28% below median its 10-year median of 39.95. Over the past 10 years, this metric has ranged from a low of 17.08 to a high of 154.93. The Drug Manufacturers industry median Interest Coverage is 13.55. Essex Bio-Technology's value of 28.89 is 113.2% above this industry median. Based on the distribution chart, Essex Bio-Technology ranks #231 out of 685 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Essex Bio-Technology has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Essex Bio-Technology's Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Essex Bio-Technology ranks #231 out of 685 companies for Interest Coverage. This puts Essex Bio-Technology in the upper half of its industry. The industry median Interest Coverage is 13.55. Essex Bio-Technology's value of 28.89 is 113.2% above this benchmark. Historically, Essex Bio-Technology's own Interest Coverage has ranged from 17.08 to 154.93 over the past decade. While the company's 10-year median is 39.95 vs. the industry median of 13.55, Essex Bio-Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 13.55, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Essex Bio-Technology's current Interest Coverage of 28.89 is 113.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Essex Bio-Technology and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 13.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Essex Bio-Technology's current Interest Coverage is 28.89, which is 28% below median its own 10-year median of 39.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Essex Bio-Technology stock overvalued right now?
Based on GuruFocus' analysis, Essex Bio-Technology (HKSE:01061) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$3.13, compared to a current price of HK$2.29 — trading 26.8% below its estimated fair value. The current Interest Coverage is 28.89, which is 28% below median its 10-year median of 39.95 and 113.2% above the Drug Manufacturers industry median of 13.55. Essex Bio-Technology's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Essex Bio-Technology (HKSE:01061), the current Interest Coverage is 28.89 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Essex Bio-Technology (HKSE:01061) Overvalued in 2026?
Based on GuruFocus' analysis, Essex Bio-Technology stock appears to be undervalued.
The current stock price of HK$2.29 is trading 26.8% below its estimated GF Value™ of HK$3.13.
GuruFocus considers Essex Bio-Technology to be Modestly Undervalued.
Key valuation signals for HKSE:01061:
Interest Coverage: 28.89 (28% below median its 10-year median of 39.95)
GF Value™: HK$3.13 vs. price of HK$2.29 (26.8% below fair value)
Industry Position: 113.2% above the Drug Manufacturers median (#231 of 685)
No single metric tells the full story. See the HKSE:01061 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Essex Bio-Technology Ltd is principally engaged in investment holding and development, manufacture, and sale of biologic drugs in the People's Republic of China. The company is made up of segments of Ophthalmology products and Surgical products. Its products under Ophthalmology include the Beifushu series, Tobramycin Eye Drops, Levofloxacin Eye Drops, and Sodium Hyaluronate Eye Drops. The products under Surgical include the Beifuji series, Carisolv dental caries removal gel, and mouthwash. The majority of the group's revenue comes from the PRC, also operates in Hong Kong and other countries.
86GF Score
Get the complete analysis for HKSE:01061
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01061 has been successfully added to your 
